

Terumo Announces Voting Results for the Election of Directors

TOKYO, JAPAN – June 26, 2024 – Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors held at the Annual General Meeting of Shareholders today. All eight of the candidates listed on May 14 announcement were elected as directors of Terumo Corporation. Also, Terumo appointed Representative Directors at the subsequent Board of Directors held today.

The three directors serving as Audit and Supervisory Committee members, elected on June 27, 2023, continue to hold office.

1. Directors (Excluding directors who serve as Audit and Supervisory Committee Members)

Name	New position	Previous position
Toshiaki Takagi	Representative Director and Chairman of the Board	Same as on the left
Hikaru Samejima	Representative Director and Chief Executive Officer	Chief Executive Officer
Toshihiko Osada	Director and Group Senior Managing Executive Officer	Group Senior Managing Executive Officer
Kazunori Hirose	Director and Group Managing Executive Officer	Same as on the left
Norimasa Kunimoto	Director and Group Managing Executive Officer	Same as on the left
Hidenori Nishi	Independent Director	Same as on the left
Keiya Ozawa	Independent Director	Same as on the left
Mari Kogiso	Independent Director	-

2. Directors who serve as Audit and Supervisory Committee Members

Name	Current position	
Takanori Shibazaki	Director (Full-time Audit and Supervisory Committee Member)	
Masaichi Nakamura	Independent Director (Audit and Supervisory Committee Member)	
Soichiro Uno	Independent Director (Audit and Supervisory Committee Member)	

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.